MARKED REDUCTION OF STRIATAL DOPAMINE-D2 RECEPTORS AS DETECTED BY 123IBZM-SPECT IN A WILSONS-DISEASE PATIENT WITH GENERALIZED DYSTONIA

被引：25

作者：

SCHWARZ, J

TATSCH, K

VOGL, T

KIRSCH, CM

TRENKWALDER, C

ARNOLD, G

GASSER, T

OERTEL, WH

机构：

[1] Department of Neurology, Klinikum Großhadern, Ludwig-Maximilians-University

[2] Department of Radiology, Ludwig-Maximilians-University, Munich

来源：

MOVEMENT DISORDERS | 1992年 / 7卷 / 01期

关键词：

WILSONS DISEASE; DYSTONIA; IBZM-SPECT; MRI; APOMORPHINE;

D O I：

10.1002/mds.870070111

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

[I-123]iodobenzamide-single photon emission computed tomography (IBZM-SPECT) was employed to study the distribution of dopamine D2 receptors in a patient with biochemically proven Wilson's disease presenting with generalized dystonia. IBZM is a dopamine D2 receptor antagonist with high affinity and specific binding to basal ganglia detectable by SPECT. IBZM-SPECT in this patient (age, 20 years) displayed a striatum to frontal cortex ratio of 1.2 compared to 1.55 +/- 0.05 (mean +/- SD) in normal controls (n = 7; mean age, 53.3 years). In parallel with this finding, MRI with heavily T2-weighted sequences showed atrophy and low signal intensity changes of the basal ganglia. There was no improvement of dystonia after a subcutaneous injection of apomorphine. In contrast, IBZM-SPECT of a neurologically asymptomatic Wilson's disease patient (age, 21 years) displayed a striatum to frontal cortex ratio of 1.6. The MRI scan of this patient was normal. It is suggested that the observed apomorphine-unresponsive generalized dystonia in this Wilson's disease patient is related to striatal lesions proven by IBZM-SPECT and MRI.

引用

页码：58 / 61

页数：4

共 14 条

[1]

Horoupian DS, Sternlieb I, Scheinberg IH., Neuropathological findings in penicillamine‐treated patients with Wilson's disease, Clin Neuropathol, 7, pp. 62-67, (1988)

[2]

Marsden CD, Obeso JA, Zarranz JJ, Lang AE., The anatomical basis of symptomatic hemidystonia, Brain, 198, pp. 463-483, (1985)

[3]

Dawson TM, Gehlert DR, Wamsley JK., Quantitative autoradiographic demonstration of high and low affinity agonist binding of D2 dopamine receptors, Clin Res, 33, (1985)

[4]

Kung HF, Alavi A, Chang W, Et al., In vivo SPECT imaging of dopamine D2 receptors: initial studies with iodine‐123‐IBZM in humans, J Nucl Med, 31, pp. 573-579, (1990)

[5]

Bruke T, Podreka I, Angelberger P, Et al., Imaging of dopamine D2 receptors with SPECT: Studies in different neuropsychiatric disorders, J Cereb Blood Flow Metab, 11, pp. 220-228, (1991)

[6]

Oertel WH, Gasser T, Trenkwalder C, Ippisch R, Poewe W., Apomorphine test for dopaminergic responsiveness, Lancet, 1, pp. 1262-1263, (1989)

[7]

Hughes A, Lees AJ, Stern GM., Use of apomorphine to test for dopaminergic responsiveness, Lancet, 1, pp. 8706-8710, (1990)

[8]

Wilson SAK., Progressive lenticular degenerations: a familial nervous disease associated with cirrhosis of the liver, Brain, 34, pp. 295-507, (1912)

[9]

Duchen LW, Jacobs JM., Nutritional deficiencies and metabolic disorders, Greenfield's neuropathology, pp. 595-602, (1984)

[10]

Aisen AM, Martel W, Gabrielsen TO, Et al., Wilson's disease of the brain: MR imaging, Radiology, 157, pp. 137-141, (1985)

← 1 2 →